NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research has pumped C$52 million ($49.3 million) into several genomic and translational research programs aimed at developing new diagnostics and treatments for cancer, OICR said today.

The new investment will concentrate on supporting programs and research areas that the institute deems to be of high interest, including ones centering on cancer genomics and stem cells, drug discovery, informatics, and pathology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.